Streamex Corp. STEX
Corp. (formerly BioSig Technologies, Inc.) ("Streamex," "we," "us," or the "Company")
was originally formed as a Nevada corporation in February 2009 and reincorporated in Delaware in April 2011 through a merger with its
wholly owned Delaware subsidiary, with the Delaware entity surviving.
May 28, 2025, the Company completed the acquisition of Streamex Exchange Corporation ("Streamex Exchange"), a corporation
Last close
0.44
2026-10-23
Market cap
$51.2M
2026-06-30 share count
52-week range
0.35 - 5.26
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-9.65
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $40.0K | $18.0K | $286.0K | $441.0K | $0 | — | — | — | — |
| Cost of revenue | — | — | — | $57.0K | $199.0K | $0 | — | — | — | — |
| Gross profit | — | — | $18.0K | $229.0K | $242.0K | $0 | — | — | — | — |
| R&D | $31.0K | $832.0K | $5.1M | $5.8M | $5.6M | $18.1M | $9.7M | $4.4M | $4.8M | $2.7M |
| SG&A | $67.5M | $11.6M | $23.1M | $21.4M | $27.9M | $41.0M | $24.8M | $12.9M | $8.1M | $8.5M |
| Total operating expenses | $71.1M | $12.9M | $28.5M | $27.5M | $33.7M | $59.2M | $34.6M | $17.3M | $12.9M | $11.2M |
| Operating income | -$71.1M | -$12.9M | -$28.5M | -$27.3M | -$33.4M | -$59.2M | -$34.6M | -$17.3M | -$12.9M | -$11.2M |
| Interest expense | $1.6M | $11.0K | $9.0K | $3.0K | $2.0K | $45.0K | $133.0K | $10.9K | $75 | $1 |
| Pre-tax income | -$464.0M | -$10.3M | -$28.7M | -$27.3M | -$32.9M | -$59.1M | -$34.5M | -$17.3M | -$12.7M | -$11.6M |
| Income tax | $1.3M | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$462.8M | -$10.3M | -$29.0M | -$27.1M | -$31.9M | -$52.2M | -$34.1M | -$18.1M | -$12.7M | -$11.6M |
| EPS, basic | -9.65 | -0.75 | -3.95 | -6.33 | — | — | — | — | — | — |
| EPS, diluted | -9.65 | -0.75 | -3.95 | -6.33 | — | -1.87 | -1.65 | -1.25 | -1.25 | -0.60 |
| Shares, diluted (wtd. avg.) | 48.0M | 14.0M | 7.4M | 4.3M | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.3M | $142.0K | $190.0K | $357.0K | $11.7M | $28.3M | $12.1M | $4.5M | $1.5M | $1.1M |
| Receivables | — | $109.0K | $24.0K | $9.0K | $0 | — | — | — | — | — |
| Inventory | — | — | — | $336.0K | $1.9M | $768.0K | $578.0K | $0 | — | — |
| Total current assets | $71.9M | $388.0K | $528.0K | $1.1M | $13.9M | $29.3M | $12.8M | $4.6M | $1.7M | $1.2M |
| Property, plant and equipment | $25.0K | $85.0K | $509.0K | $665.0K | $652.0K | $289.0K | $180.4K | $44.3K | $18.7K | $24.2K |
| Goodwill | $71.0M | — | — | — | — | — | — | — | — | — |
| Other intangibles | $44.6M | $269.0K | $288.0K | $307.0K | $326.0K | $346.0K | $365.0K | $268.8K | $0 | — |
| Total assets | $187.5M | $842.0K | $1.8M | $4.1M | $15.5M | $30.4M | $14.2M | $5.0M | $1.7M | $1.2M |
| Accounts payable | $3.0M | $2.1M | $4.1M | $2.9M | $2.2M | $4.7M | $1.5M | $954.7K | $473.1K | $373.1K |
| Total current liabilities | $42.8M | $2.3M | $4.6M | $3.3M | $2.6M | $5.1M | $2.0M | $1.2M | $4.0M | $3.0M |
| Total liabilities | $54.2M | $2.3M | $4.7M | $3.7M | $3.0M | $5.1M | — | — | — | — |
| Retained earnings | -$718.1M | -$255.3M | -$245.0M | -$216.0M | -$188.9M | -$157.0M | -$104.8M | -$70.7M | -$56.5M | -$43.8M |
| Total equity | $133.2M | -$1.5M | -$3.0M | $292.0K | $12.5M | $25.2M | $11.7M | $3.3M | -$3.2M | -$2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.4M | -$4.8M | -$17.3M | -$21.7M | -$26.4M | -$26.6M | -$15.5M | -$10.3M | -$7.5M | -$5.1M |
| Depreciation and amortisation | $60.0K | $169.0K | $342.0K | $293.0K | $198.0K | $94.0K | $54.0K | $12.4K | $11.7K | $10.5K |
| Stock-based compensation | $869.0K | $15.0K | $230.0K | — | $0 | $1.3M | $0 | $6.6M | $4.7M | $6.0M |
| Capital expenditure | — | — | $186.0K | $168.0K | $542.0K | $87.0K | $177.0K | $38.0K | $9.4K | $16.3K |
| Investing cash flow | -$24.2M | — | -$186.0K | -$168.0K | -$542.0K | -$87.0K | -$285.0K | -$307.7K | -$9.4K | -$16.3K |
| Financing cash flow | $54.9M | $4.7M | $17.3M | $10.6M | $10.3M | $42.8M | $23.4M | $13.5M | $8.0M | $5.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014376.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $441.0K | $286.0K | $18.0K | $40.0K | — |
| Gross profit | — | — | — | — | $0 | $242.0K | $229.0K | $18.0K | — | — |
| Net income | -$11.6M | -$12.7M | -$18.1M | -$34.1M | -$52.2M | -$31.9M | -$27.1M | -$29.0M | -$10.3M | -$462.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |